Toggle light / dark theme

Antennas receive and transmit electromagnetic waves, delivering information to our radios, televisions, cellphones and more. Researchers in the McKelvey School of Engineering at Washington University in St. Louis imagines a future where antennas reshape even more applications.

Their new metasurfaces, ultra-thin materials made of tiny nanoantennas that can both amplify and control light in very precise ways, could replace conventional refractive surfaces from eyeglasses to smartphone lenses and improve dynamic applications such as augmented reality/ and LiDAR ( and ranging).

While metasurfaces can manipulate light very precisely and efficiently, enabling powerful optical devices, they often suffer from a major limitation: Metasurfaces are highly sensitive to the , meaning they can only interact with light that is oriented and traveling in a certain direction. While this is useful in polarized sunglasses that block glare and in other communications and imaging technologies, requiring a specific polarization dramatically reduces the flexibility and applicability of metasurfaces.

In 2025, Vetek Association is a founding partner in organizing several international conferences. In addition to the main longevity event in Israel – the Longevity Nation conference that will take place in Bar-Ilan University, on June 25–26 https://longevitynation.org/ Registration https://longevitynation.org/register-and-donate/

And community meetups in Israel https://www.longevityisrael.org/meetups/.

A cancer therapy that uses genetically engineered immune cells, called CAR T-cells, has kept a person free of a potentially fatal nerve tumour for a record-breaking 18 years.⁠ ⁠ “This is, to my knowledge, the longest-lasting complete remission in a patient who received CAR T-cell therapy,” says Karin Straathof at University College London, who wasn’t involved in the treatment. “This patient is cured,” she says.⁠ ⁠ Doctors use CAR T-cell therapy to treat some kinds of blood cancer, like leukaemia. To do this, they collect a sample of T-cells, which form part of the immune system, from a patient’s blood and genetically engineer them to target and kill cancer cells. They then infuse the modified cells back into the body. In 2022, a follow-up study found that this approach had put two people with leukaemia into remission for around 11 years, a record at the time.⁠ ⁠

In a study published in Science Advances, Mayo Clinic researchers found a new immunotherapy target called a cryptic antigen that may be key in helping the immune system fight tumors in ovarian cancer.

Cryptic antigens are part of a protein — known as epitopes — that are usually hidden or inaccessible to the immune system and may be present in tumor cells.

“These findings underscore the need to look at alternate sources of target antigens for ovarian cancer,” says Marion R. Curtis, Ph.D., a Mayo Clinic senior associate consultant in immunology and senior author of the study.

Curing Cancer In A Flash — Dr. Bill Loo, Jr., MD, PhD — Professor, Stanford Medicine / Co-Founder, TibaRay Inc


Dr. Billy W. Loo Jr., MD PhD (https://med.stanford.edu/profiles/6839) is a Professor of Radiation Oncology, a member of the Stanford Cancer Institute, the Molecular Imaging Program at Stanford (MIPS), and of Bio-X Interdisciplinary Biosciences Institute. He is a physician-scientist Radiation Oncologist and Bioengineer who directs the Thoracic Radiation Oncology Program and is Principal Investigator of the FLASH Sciences Lab at Stanford (https://med.stanford.edu/loo-lab.html).

Dr. Loo’s clinical specialty is precision targeted radiotherapy for lung/thoracic cancers, including stereotactic ablative radiotherapy (SABR). Dr. Loo is a recognized expert in thoracic cancers serving on multiple national committees (including as writing member or vice-chair) that publish clinical guidelines on the treatment of lung cancer and other thoracic malignancies, particularly the National Comprehensive Cancer Network (NCCN).

British physician and microbiologist Alexander Fleming, discoverer of penicillin nearly 100 years ago, was the first to warn of the dangers of antibiotic resistance.

In his 1945 Nobel Prize speech, 27 years after his breakthrough discovery, Fleming put the world on notice foretelling a potentially dark future for his miracle drug in the event of abuse or overuse of the medication. It was a warning that spelled trouble ahead for a vast segment of the pharmacopeia known as antimicrobial drugs.

Now, microbiologists in Hungary and China are collaborating on ways to predict drug resistance among strains of Staphylococcus aureus when exposed to antibiotics in the drug development pipeline—drugs that have yet to reach the marketplace.

Quantum computers, which operate leveraging quantum mechanics phenomena, could eventually tackle some optimization and computational problems faster and more efficiently than their classical counterparts. Instead of bits, the fundamental units of information in classical computers, quantum computers rely on qubits (quantum bits), which can be in multiple states at once.

Silicon-based quantum dots, semiconductor-based structures that trap individual electrons, have been widely used as qubits, as the spin state of the electrons they confine can be leveraged to encode information. Despite their promise, many quantum computers developed so far are susceptible to decoherence, which entails the disruption of qubit states due to their interaction with the surrounding environment.

Researchers at the University of Rochester recently set out to experimentally realize a so-called nuclear-spin dark state, a condition that has been theorized to improve the performance of quantum computers, suppressing undesirable interactions and thus reducing decoherence. Their paper, published in Nature Physics, demonstrates the potential of this state for reducing decoherence in and thus potentially improving control over quantum information processing.